The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma (original) (raw)

Abstract

sparkles

AI

This study investigates the expression of the serine protease tumor-associated differentially expressed gene-15 (TADG-15; matriptase/MT-SP1) in cervical carcinoma. It highlights the enzyme's potential role in tumor progression and its significant overexpression in both squamous cell and adenocarcinoma cervical tissues. Results indicate that TADG-15 could serve as a diagnostic biomarker and therapeutic target for cervical cancer.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (32)

  1. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987;907:191-207.
  2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metasta- sis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
  3. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992;10:145-155.
  4. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 2001; 276:857-860.
  5. Diamandis EP, Yousef GM. Human tissue kallikreins: a fam- ily of new cancer biomarkers. Clin Chem. 2002;48:1198 - 1205.
  6. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate can- cer. Urology. 2002;59:2-8.
  7. Yousef GM, Scorilas A, Nakamura T, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast can- cer. Breast Cancer Res Treat. 2003;78:149 -158.
  8. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kal- likrein 6 (hK6): a new potential serum biomarker for diag- nosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21:1035-1043.
  9. Bharaj BB, Luo LY, Jung K, Stephan C, Diamandis EP. Iden- tification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with pros- tate, breast, testicular, and ovarian cancers. Prostate. 2002; 51:35-41.
  10. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002;62:295-300.
  11. Luo LY, Katsaros D, Scorilas A, et al. The serum concentra- tion of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003; 63:807-811.
  12. Yousef GM, Fracchioli S, Scorilas A, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol. 2003;119:346 -355.
  13. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molec- ular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem. 1999; 274:18231-18236.
  14. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix- degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 1993;53:1409 -1415.
  15. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol. 2001;158:1301-1311.
  16. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 2000; 275:36720 -36725.
  17. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as sub- strates. J Biol Chem. 2000;275:26333-26342.
  18. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmem- brane serine protease: a potential candidate for early diag- nosis and therapeutic intervention. Tumour Biol. 2001;22: 104 -114.
  19. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overex- pressed in ovarian cancer. Cancer Res. 1997;57:2884 -2887.
  20. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 1999;59:4435-4439.
  21. Underwood LJ, Shigemasa K, Tanimoto H, et al. Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta. 2000;1502:337-350.
  22. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ. Increased expression of protease M in ovarian tumors. Tumour Biol. 2001;22:11-18.
  23. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(ϩ) and CD8(ϩ) lym- phocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervi- cal cancer. J Virol. 1999;73:5402-5410.
  24. Brand K. Cancer gene therapy with tissue inhibitors of met- alloproteinases (TIMPs). Curr Gene Ther. 2002;2:255-271.
  25. Mignatti P, Rifkin DB. Biology and biochemistry of protein- ases in tumor invasion. Physiol Rev. 1993;73:161-195.
  26. Lamszus K, Jin L, Fuchs A, et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest. 1997;76:339 -353.
  27. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Uroki- nase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130 -135.
  28. DiSaia PJ, Creasman WT. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology (5th edition). St. Louis: Mosby-Year Book, 1997:51-106.
  29. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519 -1526.
  30. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondu- rant KL, Santin AD. Novel target antigens for dendritic cell- based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002;2:97-105.
  31. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimu- late CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409 -417.
  32. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165: 3797-3803.